Microbot Medical Signs Phase 2 Collaboration Agreement with Corewell Health to Advance Remote Telesurgery Using the LIBERTY® Endovascular Robotic System
Microbot Medical Inc. (Nasdaq: MBOT) has entered a Phase 2 collaboration agreement with Corewell Health to advance remote telesurgery using the LIBERTY® Endovascular Robotic System. This follows the successful completion of Phase 1, which demonstrated LIBERTY's technical capabilities for endovascular interventions. The objective of Phase 2 is to develop and demonstrate new telesurgery capabilities by performing simulated cardiovascular interventional procedures across two Corewell Health facilities located 5 miles apart.
The project is led by Dr. Ryan Madder, who recently published a manuscript highlighting the technical success of coronary guidewire and stent delivery using LIBERTY in a pre-clinical study. Microbot Medical's CEO, Harel Gadot, emphasized that incorporating telesurgery capabilities is important to their long-term strategy for LIBERTY, aiming to increase access to care for patients in remote locations.
Microbot Medical Inc. (Nasdaq: MBOT) ha stipulato un accordo di collaborazione Fase 2 con Corewell Health per avanzare nella telesurgery remota utilizzando il Sistema Robotico Endovascolare LIBERTY®. Questo segue il completamento con successo della Fase 1, che ha dimostrato le capacità tecniche di LIBERTY per le interventi endovascolari. L'obiettivo della Fase 2 è sviluppare e dimostrare nuove capacità di telesurgery eseguendo procedure interventistiche cardiovascolari simulate in due strutture di Corewell Health situate a 8 km di distanza.
Il progetto è guidato dal Dr. Ryan Madder, che ha recentemente pubblicato un manoscritto evidenziando il successo tecnico nella consegna di guidewire coronariche e stent utilizzando LIBERTY in uno studio pre-clinico. L'Amministratore Delegato di Microbot Medical, Harel Gadot, ha sottolineato che l'integrazione delle capacità di telesurgery è importante per la loro strategia a lungo termine per LIBERTY, con l'obiettivo di aumentare l'accesso alle cure per i pazienti in località remote.
Microbot Medical Inc. (Nasdaq: MBOT) ha firmado un acuerdo de colaboración de Fase 2 con Corewell Health para avanzar en la telesurgeonía remota utilizando el Sistema Robótico Endovascular LIBERTY®. Esto sigue la exitosa finalización de la Fase 1, que demostró las capacidades técnicas de LIBERTY para las intervenciones endovasculares. El objetivo de la Fase 2 es desarrollar y demostrar nuevas capacidades de telesurgeonía realizando procedimientos de intervención cardiovascular simulados en dos instalaciones de Corewell Health ubicadas a 8 kilómetros de distancia.
El proyecto está liderado por el Dr. Ryan Madder, quien recientemente publicó un manuscrito que destaca el éxito técnico de la entrega de guías coronarias y stents utilizando LIBERTY en un estudio preclínico. El CEO de Microbot Medical, Harel Gadot, enfatizó que incorporar capacidades de telesurgeonía es importante para su estrategia a largo plazo para LIBERTY, con el objetivo de aumentar el acceso a la atención para pacientes en ubicaciones remotas.
마이크로봇 메디컬 주식회사(Nasdaq: MBOT)는 LIBERTY® 혈관 로봇 시스템을 사용하여 원격 원격 수술을 발전시키기 위해 Corewell Health와 함께 2단계 협력 계약을 체결했습니다. 이는 LIBERTY의 혈관 내 개입 기술력을 입증한 1단계 성공적 완료에 이어지는 것입니다. 2단계의 목표는 Corewell Health에 위치한 8km 떨어진 두 시설에서 심 simulated 심혈관 개입 절차를 수행하여 새로운 원격 수술 기능을 개발하고 시연하는 것입니다.
이 프로젝트는 라이언 매더 박사가 이끌고 있으며, 그는 최근 LIBERTY를 사용하여 관상 동맥 가이드 와이어와 스텐트를 전달하는 기술적 성공을 강조한 논문을 발표했습니다. Microbot Medical의 CEO인 하렐 가돗은 원격 수술 기능 통합이 LIBERTY에 대한 장기 전략에 중요하다고 강조하며, 이를 통해 원거리 지역에 있는 환자들의 진료 접근성을 높이는 것을 목표로 하고 있습니다.
Microbot Medical Inc. (Nasdaq: MBOT) a signé un accord de collaboration de phase 2 avec Corewell Health pour faire avancer la téléchirurgie à distance en utilisant le Système Robotique Endovasculaire LIBERTY®. Cela fait suite à l'achèvement réussi de la phase 1, qui a démontré les capacités techniques de LIBERTY pour les interventions endovasculaires. L'objectif de la phase 2 est de développer et de démontrer de nouvelles capacités de téléchirurgie en effectuant des procédures d'intervention cardiovasculaire simulées dans deux établissements de Corewell Health situés à 8 km l'un de l'autre.
Le projet est dirigé par le Dr Ryan Madder, qui a récemment publié un manuscrit mettant en évidence le succès technique de la livraison de guides coronaires et de stents en utilisant LIBERTY dans une étude préclinique. Le PDG de Microbot Medical, Harel Gadot, a souligné que l'intégration des capacités de téléchirurgie est importante pour leur stratégie à long terme pour LIBERTY, visant à augmenter l'accès aux soins pour les patients dans des zones éloignées.
Microbot Medical Inc. (Nasdaq: MBOT) hat eine Kooperationsvereinbarung der Phase 2 mit Corewell Health geschlossen, um die Remote-Telesurgeonien mit dem LIBERTY® Endovaskulären Robotersystem voranzutreiben. Dies folgt auf den erfolgreichen Abschluss der Phase 1, die die technischen Fähigkeiten von LIBERTY für endovaskuläre Eingriffe demonstrierte. Ziel der Phase 2 ist es, neue Telesurgery-Funktionen zu entwickeln und zu demonstrieren, indem simulierte kardiovaskuläre Eingriffsverfahren in zwei Corewell Health-Einrichtungen durchgeführt werden, die 8 km voneinander entfernt sind.
Das Projekt wird von Dr. Ryan Madder geleitet, der kürzlich ein Manuskript veröffentlicht hat, das den technischen Erfolg der Lieferung von koronaren Führungsdrähten und Stents mit Hilfe von LIBERTY in einer präklinischen Studie hervorhebt. Der CEO von Microbot Medical, Harel Gadot, betonte, dass die Integration von Telesurgery-Funktionen für ihre langfristige Strategie von LIBERTY von Bedeutung ist, um den Zugang zur Versorgung für Patienten in entlegenen Gebieten zu erhöhen.
- Successful completion of Phase 1 collaboration with Corewell Health
- Advancement to Phase 2 agreement for remote telesurgery development
- Publication of positive pre-clinical study results in a respected medical journal
- Potential to increase access to care for patients in remote locations
- None.
Insights
Microbot Medical's collaboration with Corewell Health marks a significant step in advancing remote telesurgery capabilities. The successful completion of Phase 1, which demonstrated LIBERTY's technical viability for remote procedures, sets a promising foundation for Phase 2. This phase aims to develop and demonstrate simulated cardiovascular interventional procedures across two Corewell Health facilities, potentially revolutionizing access to specialized care in remote areas.
The publication of Dr. Madder's manuscript in a prestigious journal (
The LIBERTY® Endovascular Robotic System represents a cutting-edge advancement in medical robotics. The system's ability to perform remote telesurgery across facilities 5 miles apart demonstrates its robust connectivity and precision control. This technology could significantly impact healthcare delivery by:
- Enabling specialists to perform procedures remotely, addressing physician shortages in rural areas
- Reducing travel time and costs for patients needing specialized care
- Potentially improving procedural outcomes through robotic precision
As telemedicine continues to grow, LIBERTY's capabilities align well with the industry trend towards remote healthcare solutions. The successful development of this technology could position Microbot Medical as a leader in the expanding field of robotic telesurgery.
This collaboration agreement signals positive momentum for Microbot Medical (NASDAQ: MBOT). Key financial implications include:
- Potential for expanded market reach through telesurgery capabilities, possibly leading to increased adoption and revenue streams
- Validation from a major healthcare system (Corewell Health) could attract investor interest and partnerships
- R&D investment in telesurgery aligns with growing demand for remote healthcare solutions, potentially increasing the company's long-term value proposition
However, investors should note that the technology is still in development and commercialization timelines remain uncertain. While the news is encouraging, it's important to consider the company's overall financial health, regulatory hurdles and market competition when assessing its investment potential.
The agreement follows the successful completion of Phase 1 which evaluated the viability of LIBERTY as a remote telesurgery platform
The objective of Phase 2 is to develop and demonstrate new telesurgery capabilities by performing simulated interventional procedures between two facilities within the Corewell Health system
BRAINTREE, Mass., Aug. 22, 2024 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative LIBERTY® Endovascular Robotic System, announces that it entered into a Phase 2 collaboration agreement with Corewell Health™ that will continue their collaboration to advance remote telesurgery for endovascular procedures. The Company had previously announced positive results from the first phase, which demonstrated LIBERTY’s technical capabilities and outlined potential future applications in a range of endovascular interventions, including the feasibility of LIBERTY to support the remote telesurgery project.
During Phase 2, the Company and Corewell Health will work together to develop the capabilities to perform simulated cardiovascular interventional procedures with LIBERTY across two sites within the Corewell Health system which are 5 miles apart.
The project is led by Ryan Madder, M.D., Section Chief of Interventional Cardiology and Director of the Cardiac Cath Lab at Corewell Health in West Michigan. Following the completion of Phase 1, Dr. Madder and colleagues published a manuscript in the Journal of the American College of Cardiology: Cardiovascular Interventions, highlighting the Technical Success of Coronary Guidewire and Stent Delivery Using a Novel Miniaturized Robotic System in a Pre-Clinical Study.
“Incorporating telesurgery capabilities is an important part of our long-term strategy for LIBERTY,” said Harel Gadot, CEO, President and Chairman of Microbot Medical. “We believe that physicians in the U.S. and around the globe want to increase access to care for patients in remote locations, and we are excited to continue our collaboration with Corewell Health and Dr. Madder on this next phase of development.”
Dr. Madder’s manuscript is available at: https://doi.org/10.1016/j.jscai.2024.102148
About Microbot Medical
Microbot Medical Inc. (NASDAQ: MBOT) is a clinical- stage medical device company that specializes in transformational micro-robotic technologies, with the goals of improving clinical outcomes for patients and increasing accessibility through the natural and artificial lumens within the human body.
The Investigational LIBERTY® Endovascular Robotic Surgical System aims to improve the way surgical robotics are being used in endovascular procedures today, by eliminating the need for large, cumbersome, and expensive capital equipment, while reducing radiation exposure and physician strain. The Company believes the LIBERTY® Endovascular Robotic Surgical System’s remote operation has the potential to be the first system to democratize endovascular interventional procedures.
Further information about Microbot Medical is available at http://www.microbotmedical.com.
Safe Harbor
Statements to future financial and/or operating results, future growth in research, technology, clinical development, and potential opportunities for Microbot Medical Inc. and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management, constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and the Federal securities laws. Any statements that are not historical fact (including, but not limited to statements that contain words such as “will,” “believes,” “plans,” “anticipates,” “expects” and “estimates”) should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, market conditions, risks inherent in the development and/or commercialization of the LIBERTY® Endovascular Robotic Surgical System, the outcome of its studies to evaluate the LIBERTY® Endovascular Robotic Surgical System, uncertainty in the results of pre-clinical and clinical trials or regulatory pathways and regulatory approvals, including whether the Company’s pivotal study in humans is successful, any failure or inability to recruit physicians and clinicians to serve as primary investigators to conduct regulatory studies which could adversely affect or delay such studies, disruptions resulting from new and ongoing hostilities between Israel and the Palestinians and other neighboring countries, any lingering uncertainty resulting from the COVID-19 pandemic, need and ability to obtain future capital, and maintenance of intellectual property rights. Additional information on risks facing Microbot Medical can be found under the heading “Risk Factors” in Microbot Medical’s periodic reports filed with the Securities and Exchange Commission (SEC), which are available on the SEC’s web site at www.sec.gov. Microbot Medical disclaims any intent or obligation to update these forward-looking statements, except as required by law.
Investor Contact:
Michal Efraty
FAQ
What is the purpose of Microbot Medical's Phase 2 collaboration with Corewell Health for MBOT stock?
What were the results of the Phase 1 collaboration between Microbot Medical and Corewell Health for MBOT?
Who is leading the telesurgery project for Microbot Medical's LIBERTY system (MBOT)?
What recent publication supports the potential of Microbot Medical's LIBERTY system for MBOT investors?
